Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.

Leukemia research - 1 Jul 2011

Oyekunle Anthony A, Castagnetti Fausto, Gugliotta Gabriele, Soverini Simona, Baccarani Michele, Rosti Gianantonio

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl
Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Share to Thiazoles

Source

Identifiers

PMID: 21489624
DOI: 10.1016/j.leukres.2011.03.021

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.PMID 21489624Read ↗

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.Semantic proximity Read ↗

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.Semantic proximity Read ↗

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.Semantic proximity Read ↗

Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation.Semantic proximity Read ↗

T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.Semantic proximity Read ↗

New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors?Semantic proximity Read ↗

Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.Semantic proximity Read ↗

Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.Semantic proximity Read ↗

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.Semantic proximity Read ↗

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.Semantic proximity Read ↗

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.